Pharmacodynamic effect of N-acetylcysteine as adjunctive therapy in mild systemic lupus erythematosus patients

Tropical Journal of Pharmaceutical Research

Volumn 10, Issue 2, 2011, Pages 141-146

  Tewthanom, K ^a   Janwityanujit, S ^b   Totemchockchyakarn, K ^b   Panomvana, D ^c  

^a SILPAKORN UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Adjunctive therapy; N Acetylcysteine; Pharmacodynamics; Systemic lupus erythematosus

Indexed keywords

ACETYLCYSTEINE; AZATHIOPRINE; GLUTATHIONE; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; MALONALDEHYDE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE;

ADJUVANT THERAPY; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FOLLOW UP; HEADACHE; HUMAN; LIPID PEROXIDATION; PHARMACODYNAMICS; PROTEIN BLOOD LEVEL; RASH; SYMPTOM; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION;

EID: 79955929798     PISSN: 15965996     EISSN: 15969827     Source Type: Journal    
DOI: 10.4314/tjpr.v10i2.66554     Document Type: Article

References (23)

1. Thorn Research Inc. N-acetylcysteine monograph. Alternative Medicine Review 2000; 5: 467-471.
2. Pastore A, Federici G, Bertini E, Piemonte F. Analysis of glutathione: implication in redox and detoxification. Clinica Chemica Acta 2003; 333: 19-39.
3. Buhl R, Jaffe HA, Holroyd KJ, Wells FB, Mastrangeli A, Saltini C, Cantin AM, Crystal RG. Systemic glutathione deficiency in symptom-free HIV-seropositive individuals. Lancet 1989; 2(8675): 1294-1298.
4. Lang CA, Mills BJ, Lang HL, Liu MC, Usui WM, Richie JR, Mastropaolo W, Murrell SA. High blood glutathione levels accomany excellent physical and mental health in women ages 60 to 103 years. J Lab Clin Med 2002; 140: 413-417.
5. Michelet F, Gueguen R, Leroy P, Wellman M, Nicolas A, Siest G. Blood and plasma glutathione measured in healthy subjects by HPLC: relation to sex, aging, biological variables, and life habits. Clin Chem 1995; 41(10): 1509-1517.
6. Kurien BT, Scofield RH. Lipid peroxidation in systemic lupus erythematosus. Indian J Exp Biol 2006; 44(5): 349-56.
7. Frostegard J, Svenunsson E, Wu R, Gunnarsson I, Lundberge IE, Klareskog L, Horkko S, Witztum JL. Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestation. Arthritis Rheum 2005; 52: 192-200.
8. Alves JD, Ames PR. Atherosclerosis, oxidative stress and auto-antibodies in systemic lupus erythematosus and primary antiphospholipid syndrome. Immunobiology 2003; 207(1): 23-28.
9. Kurien BT. Scofield RH. Free radical mediated peroxidative damage in systemic lupus erythematosus. Life Science 2003; 73: 1655-1666.
10. Taysi S, Gul M, Sari RA, Akcay F, Bakan N. Serum oxidant/antioxidant status in patients with systemic lupus erythematosus. Clin Chem Lab Med 2002; 40: 684-688.
11. Ames PRJ, Alves J, Murat I, Isenberg DA, Nouroozzadeh J. Oxidative stress in sytemic lupus erythematosus and allied condition with vascular involvement. Rheumatology 1999; 38: 529-534.
12. Mohan IK, Das UN. Oxidant stress, anti-oxidants and essential fatty acids in systemic lupus erythematosus. Prostaglandins Leukot Essent Fatty Acids 1997; 56(3): 193-198.
13. World Medical Association Declaration of Helsinki, Ethical Principles for Medical Research Involving Human Subjects. World Med J, 2008; 54: 122-125.
14. Yagi K. Simple assay for the level of total lipid peroxides in serum or plasma. Methods Mol Biol 1998; 108: 101-106.
15. Van Zandwijk N. N-acetylcysteine (NAC) and glutathione (GSH): antioxidant and chemopreventive properties, with special reference to lung cancer. J Cell Biochem Suppl 1995; 22: 24-32.
16. Pendyala L, Creavan PJ. Pharmacokinetic and Pharmacodynamic studies of N-acetylcysteine, a potential chemopreventive agent during a Phase I trial. 1995; 4: 245-251.
17. Hultberg M, Hultberg B. The effect of different antioxidants on glutathione turnover in human cell line and their interaction with hydrogen peroxide. Chemico Biol Interaction 2006; 163: 192-198.
18. Block KI, Koch AC, Mead MN, Tothy PK, Newman RA, Gyllenhaal C. Impact of antioxidant supplementation on chemotherapeutic efficacy: a systematic review of the evidence from randomized controlled trials. Cancer Treat Rev 2007; 33(5): 407-418.
19. Atmaca G. Antioxidant effects of sulfur-containing amino acids. Yonsei Med J 2004; 45(5): 776-788.
20. Zafarullah M, Li WQ, Sylvester J, Ahmad M. Molecular mechanism of N-acetylcysteine actions. Cell Mol. Life Sci 2003; 60: 6-20.
21. Karlson EW, Watts J, Signorovitch J, Bonetti M, Wright E, Cooper GS, McAlindon TE, Costenbader KH, Massarotti EM, Fitzgerald LM, Jajoo R, Husni ME, Fossel AH, Pankey H, Ding WZ, Knorr R, Condon S, Fraser PA. Effect of glutathione S-transferase polymorphisms and proximity to hazardous waste sites on time to systemic lupus erythematosus diagnosis: results from the Roxbury lupus project. Arthritis Rheum 2007; 56(1): 244-254.
22. Zhong S, Huang M, Yang X, Liang L, Wang Y, Romkes M, Duan W, Chan E, Zhou SF. Relationship of glutathione S-transferase genotypes with side-effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosus. Br J Clin Pharmacol 2006; 62(4): 457-472.
23. Kang I, Park SH. Infectious complications in SLE after immunosuppressive therapies. Curr Opin Rheumatol 2003; 15: 528-534.